Enanta/$ENTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Ticker
- $ENTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 120
- Headquarters
- Watertown, United States
- Website
- www.enanta.com
Enanta Metrics
BasicAdvanced
$393M
-
-$2.34
0.93
-
Price and volume
Market cap
$393M
Beta
0.93
52-week high
$17.15
52-week low
$7.05
Average daily volume
214K
Financial strength
Current ratio
3.759
Quick ratio
3.619
Long term debt to equity
139.856
Total debt to equity
180.116
Interest coverage (TTM)
-4.55%
Profitability
EBITDA (TTM)
-53.819
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-96.89%
Operating margin (TTM)
-89.99%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-12.28%
Return on equity (TTM)
-70.12%
Valuation
Price to revenue (TTM)
5.599
Price to book
3.89
Price to tangible book (TTM)
3.89
Price to free cash flow (TTM)
-9.891
Free cash flow yield (TTM)
-10.11%
Free cash flow per share (TTM)
-1.365
Growth
Revenue change (TTM)
0.70%
Earnings per share change (TTM)
-45.94%
3-year revenue growth (CAGR)
-6.79%
10-year revenue growth (CAGR)
-3.15%
3-year earnings per share growth (CAGR)
-28.18%
10-year earnings per share growth (CAGR)
4.45%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Analyst projections of the future price of Enanta stock.
Bulls say / Bears say
Enanta’s Q2 2026 royalty revenue grew to $17.2 million from $14.9 million a year earlier, narrowing net loss to $13.1 million from $22.6 million and underscoring financial progress (SEC 8-K).
With $227 million in cash and marketable securities at March 31, 2026 and ongoing retained royalties, Enanta expects its balance sheet to fund operations into fiscal 2029, supporting multiple value‐driving milestones (SEC 8-K).
The virology program demonstrated positive Phase 2b zelicapavir data in high‐risk adults, with a 6.7-day improvement in time to complete RSV symptom resolution and reductions in hospitalizations, advancing toward pivotal studies (SEC 8-K).
Enanta’s revenue remains heavily reliant on AbbVie’s MAVYRET/MAVIRET royalties, with 54.5% of future royalties allocated to OMERS through June 2032, exposing cash flows to AbbVie’s HCV market share, pricing and label‐expansion dynamics (SEC 8-K).
Pending patent litigation against Pfizer over alleged infringement by Paxlovid introduces legal and financial uncertainty, with oral arguments heard in June 2026 and a Federal Circuit decision expected by end of September 2026 (SEC 8-K).
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Enanta News
AllArticlesVideos
Funds containing Enanta
AllUSDGBPEUR
Fund name | Fund size | $ENTA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.